BNT 164
Alternative Names: BNT-164; BNT-164a1; BNT-164b1Latest Information Update: 28 Aug 2023
At a glance
- Originator BioNTech
- Class RNA vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Tuberculosis
Most Recent Events
- 31 Jul 2023 Phase-I clinical trials in Tuberculosis (Prevention) in South Africa (IM) (NCT05547464)
- 08 May 2023 BioNTech plans a phase I trial for Tuberculosis (Prevention, In adults) in July 2023 (IM) (NCT05547464)
- 18 Apr 2023 Phase-I clinical trials in Tuberculosis (Prevention, In adults) in Germany (IM) (NCT05537038) (EudraCT2022-000911-29)